SG11202103586UA - Human amylin analog polypeptides and methods of use - Google Patents
Human amylin analog polypeptides and methods of useInfo
- Publication number
- SG11202103586UA SG11202103586UA SG11202103586UA SG11202103586UA SG11202103586UA SG 11202103586U A SG11202103586U A SG 11202103586UA SG 11202103586U A SG11202103586U A SG 11202103586UA SG 11202103586U A SG11202103586U A SG 11202103586UA SG 11202103586U A SG11202103586U A SG 11202103586UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- human amylin
- amylin analog
- analog polypeptides
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862744236P | 2018-10-11 | 2018-10-11 | |
PCT/US2019/055696 WO2020077129A1 (en) | 2018-10-11 | 2019-10-10 | Human amylin analog polypeptides and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103586UA true SG11202103586UA (en) | 2021-05-28 |
Family
ID=68393080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103586UA SG11202103586UA (en) | 2018-10-11 | 2019-10-10 | Human amylin analog polypeptides and methods of use |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200115430A1 (pt) |
EP (1) | EP3864031A1 (pt) |
JP (1) | JP2022504596A (pt) |
KR (1) | KR20210091705A (pt) |
CN (1) | CN113195524A (pt) |
AR (1) | AR116632A1 (pt) |
AU (1) | AU2019357621A1 (pt) |
BR (1) | BR112021006823A2 (pt) |
CA (1) | CA3116023A1 (pt) |
IL (1) | IL282079A (pt) |
MX (1) | MX2021004185A (pt) |
SG (1) | SG11202103586UA (pt) |
TW (1) | TW202028228A (pt) |
WO (1) | WO2020077129A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230040943A (ko) * | 2020-04-20 | 2023-03-23 | 아이투오 테라퓨틱스, 인코포레이티드 | 1형 당뇨병에 대한 우수한 혈당 제어를 제공하기 위한 인간 아밀린 유사체 폴리펩타이드의 용도 |
HRP20230534T1 (hr) * | 2020-09-24 | 2023-08-04 | Gubra Aps | Ham15-52 analozi s poboljšanom potencijom amilin receptora (hamy3r) |
CN113880935B (zh) * | 2021-10-25 | 2022-08-26 | 浙江肽昇生物医药有限公司 | 一种索马鲁肽全保护肽树脂的制备方法、一种索马鲁肽制备方法 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5609885A (en) | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
SK15096A3 (en) | 1993-08-09 | 1996-07-03 | Biomeasure Inc | Therapeutic peptide derivatives and a method of their application |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
US6261584B1 (en) | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
PT1238658E (pt) | 1996-02-02 | 2005-04-29 | Alza Corp | Administracao controlada de um agente activo que utiliza um sistema implantavel |
US6156331A (en) | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6132420A (en) | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
ZA981610B (en) | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
JP4215188B2 (ja) | 1997-12-22 | 2009-01-28 | インターシア セラピューティクス,インコーポレイティド | 薬剤供給を調節するデバイスのための速度調節膜 |
EP1041968B1 (en) | 1997-12-29 | 2004-03-03 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
PT1736145E (pt) | 1997-12-30 | 2012-03-16 | Intarcia Therapeutics Inc | Sistema de entrega de agente benéfico com obturador de membrana |
US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
US6903186B1 (en) | 1998-12-07 | 2005-06-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S | Analogues of GLP-1 |
DE69906132T2 (de) | 1998-12-31 | 2003-12-18 | Alza Corp | Osmotisches verabreichungsystem mit raumsparenden kolben |
US6451974B1 (en) | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
EP1180121B9 (en) | 1999-05-17 | 2004-09-08 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
WO2001045675A2 (en) | 1999-12-21 | 2001-06-28 | Alza Corporation | Valve for osmotic devices |
KR100518046B1 (ko) | 2000-05-19 | 2005-10-04 | 아밀린 파마슈티칼스, 인크. | Glp-1을 사용한 급성 관상동맥 증후군의 치료 |
HU229208B1 (en) | 2000-06-16 | 2013-09-30 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
WO2002048192A2 (en) | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
US7144863B2 (en) | 2001-06-01 | 2006-12-05 | Eli Lilly And Company | GLP-1 formulations with protracted time action |
US7163688B2 (en) | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
BR0212080A (pt) | 2001-08-23 | 2006-04-04 | Lilly Co Eli | composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1 |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
MXPA05000224A (es) | 2002-06-26 | 2005-06-03 | Alza Corp | Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos. |
US7014636B2 (en) | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
JP2006521897A (ja) | 2003-03-31 | 2006-09-28 | アルザ・コーポレーション | 内部圧力を放散する手段を備える浸透ポンプ |
US20050175701A1 (en) | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
CN103897066A (zh) | 2004-02-11 | 2014-07-02 | 安米林药品有限责任公司 | 具有可选择特性的杂合多肽 |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
CN101400698A (zh) * | 2006-03-15 | 2009-04-01 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽衍生物 |
ES2351527T3 (es) | 2006-05-30 | 2011-02-07 | Intarcia Therapeutics, Inc | Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración. |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
EP2340261B1 (en) * | 2008-10-21 | 2017-12-20 | Novo Nordisk A/S | Amylin derivatives |
WO2012162547A2 (en) * | 2011-05-25 | 2012-11-29 | Amylin Pharmaceuticals, Inc. | Long duration dual hormone conjugates |
-
2019
- 2019-10-10 AU AU2019357621A patent/AU2019357621A1/en active Pending
- 2019-10-10 AR ARP190102894A patent/AR116632A1/es unknown
- 2019-10-10 KR KR1020217013697A patent/KR20210091705A/ko unknown
- 2019-10-10 CN CN201980081630.7A patent/CN113195524A/zh active Pending
- 2019-10-10 US US16/598,915 patent/US20200115430A1/en active Pending
- 2019-10-10 MX MX2021004185A patent/MX2021004185A/es unknown
- 2019-10-10 EP EP19795724.4A patent/EP3864031A1/en active Pending
- 2019-10-10 WO PCT/US2019/055696 patent/WO2020077129A1/en active Application Filing
- 2019-10-10 CA CA3116023A patent/CA3116023A1/en active Pending
- 2019-10-10 SG SG11202103586UA patent/SG11202103586UA/en unknown
- 2019-10-10 BR BR112021006823-6A patent/BR112021006823A2/pt unknown
- 2019-10-10 JP JP2021519698A patent/JP2022504596A/ja active Pending
- 2019-10-14 TW TW108136940A patent/TW202028228A/zh unknown
-
2021
- 2021-04-05 IL IL282079A patent/IL282079A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR116632A1 (es) | 2021-05-26 |
WO2020077129A1 (en) | 2020-04-16 |
TW202028228A (zh) | 2020-08-01 |
JP2022504596A (ja) | 2022-01-13 |
BR112021006823A2 (pt) | 2021-07-27 |
KR20210091705A (ko) | 2021-07-22 |
MX2021004185A (es) | 2021-09-08 |
AU2019357621A1 (en) | 2021-05-27 |
CA3116023A1 (en) | 2020-04-16 |
CN113195524A (zh) | 2021-07-30 |
EP3864031A1 (en) | 2021-08-18 |
IL282079A (en) | 2021-05-31 |
US20200115430A1 (en) | 2020-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2595606B (en) | CRISPR-Cas effector polypeptides and methods of use thereof | |
IL272085A (en) | Multimeric T-cell modulatory polypeptides and methods of using them | |
SG11202011308VA (en) | Activatable cytokine polypeptides and methods of use thereof | |
IL297617B1 (en) | Multimeric polypeptides modulate t cells and methods for their use | |
IL272332A (en) | Antibody-displaying polypeptides and methods of their use | |
SG11202011349PA (en) | Activatable interleukin-2 polypeptides and methods of use thereof | |
IL261401A (en) | T-cell modulatory multimeric polypeptides and methods of using them | |
IL261402A (en) | T cell modulatory multimeric polypeptides and methods of using them | |
IL282079A (en) | Polypeptide analogs of human amylin and methods of use | |
IL262403A (en) | Multimeric polypeptides modulate t cells and methods for their use | |
IL290635A (en) | T-cell modulatory polypeptides and methods for their use | |
IL287192A (en) | Oligomeric polypeptides modulate t cells and methods for their use | |
IL280922A (en) | Anti-HER2 polypeptides and uses thereof | |
IL280102A (en) | Fusion protein containing PD1-4-1BBL and methods of using it | |
IL281505A (en) | Multimeric t-cell modulating polypeptides and methods for their use | |
EP4081533A4 (en) | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE | |
IL282250A (en) | Multivalent t-cell modulatory polypeptides and methods of using them | |
IL280103A (en) | Fusion protein containing SIRPalpha-4-1BBL and methods of using it | |
PT3733130T (pt) | Prótese de válvula cardíaca e seu stent | |
IL273847A (en) | Bicyclic sulfoxides and sulfones and methods of using them | |
EP4069274A4 (en) | PEPTIDE CONJUGATES AND METHODS OF USE | |
IL283782A (en) | Analosomes and methods of use | |
EP4072579A4 (en) | ALKALINE PHOSPHATASE POLYPEPTIDES AND METHODS OF USE THEREOF | |
SG11202004529XA (en) | Transformed human cell and use thereof | |
GB202201001D0 (en) | Polypeptide and use thereof |